KRAS and breast carcinoma: Sequencing information has identified mutations in other genes of interest that might be clinically relevant in breast cancer such as KRAS, NF2, SKT11, APC, and AKT2. A precise test of these breast cancer-associated genes can guide examination and preventive treatment based on the objective risk measurement such as the increased frequency of prophylactic surgery, chemoprevention, and mammography (Cui et al., 2014).